Recently, several studies have suggested that the enhancer of zeste homolog 2 (EZH2) could be a key potential factor in the development of drugs for targeted therapy in multiple tumors, including bladder cancer [17–20]. This evidence concerns the gene EZH2 and urinary bladder carcinoma.